Skip to Main Content

CHICAGO — For years, scientists said creating a drug around the KRAS protein was impossible. On Monday, Amgen (AMGN) showed it had developed a medicine that shrank tumors in 50% of lung cancer patients.

These lung cancer patients — just 10 of them because this is an early-stage clinical trial — all had tumors that tested positive for a particular mutation in KRAS, a cell-signaling protein. The 50% response rate to AMG 510 is an improvement over the 30% response rate first reported by Amgen last month. It also exceeds investor expectations.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • “The results: Five out of 10 evaluable lung cancer patients had partial responses; another four had stable disease. All five of the responders remain on AMG 510 with treatment durations ranging from seven weeks to seven months.”
    I found this sentence quite confusing and unclear: what does exactly “evaluable” stay for? You wrote “5 out of 10 had partial response, another 4 had stable disease” does it mean they did not responded? it did not progress?

Comments are closed.